UL97 kinase inhibitor
CMV UL97 kinase inhibitor
- Blocks the viral kinase that phosphorylates ganciclovir and drives capsid egress
- Active against ganciclovir-resistant UL97 mutants; antagonizes ganciclovir if the two are co-given
- Dysgeusia is the signature adverse effect; no myelosuppression
- Blocks the viral kinase that phosphorylates ganciclovir and drives capsid egress
- Active against ganciclovir-resistant UL97 mutants; antagonizes ganciclovir if the two are co-given
- Dysgeusia is the signature adverse effect; no myelosuppression
Drugs with this mechanism (1)
- Maribavir — Oral CMV UL97-kinase inhibitor for refractory post-transplant CMV infection; taste disturbance and drug interactions are prominent.
All mechanisms · Open UL97 kinase inhibitor in the interactive console ↗